Interleukin 25

Interleukin 25
Identifiers
Symbols IL25 ; IL17E
External IDs OMIM: 605658 MGI: 2155888 HomoloGene: 15429 GeneCards: IL25 Gene
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 64806 140806
Ensembl ENSG00000166090 ENSMUSG00000040770
UniProt Q9H293 Q8VHH8
RefSeq (mRNA) NM_022789 NM_080729
RefSeq (protein) NP_073626 NP_542767
Location (UCSC) Chr 14:
23.37 – 23.38 Mb		 Chr 14:
54.93 – 54.94 Mb
PubMed search

Interleukin-25 (IL-25) – also known as interleukin-17E (IL-17E)[1] – is a protein that in humans is encoded by the IL25 gene.[2][3][4]

Function

IL-25 is a cytokine that shares the sequence similarity with IL-17. This cytokine can induce NF-κB activation, and stimulate the production of IL-8. Both this cytokine and IL17B are ligands for the cytokine receptor IL17RB. Studies of the similar gene in mice suggested that this cytokine may be a proinflammatory cytokine favoring Th2-type immune response. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.[4]

IL-25 is a cytokine that belongs to the IL-17 cytokine family and is secreted by type 2 helper T cells (Th2) and mast cells.[5][6]

Clinical significance

IL-25 induces the production of other cytokines, including IL-4, IL-5 and IL-13 in multiple tissues, which stimulate the expansion of eosinophils. This cytokine is an important molecule controlling immunity of the gut[7] and has been implicated in chronic inflammation associated with the gastrointestinal tract. IL-25 can kill some types of breast cancer cells.[8]

Further, the IL-25 gene has been identified in a chromosomal region associated with autoimmune diseases of the gut such as inflammatory bowel disease (IBD), although no direct evidence suggests that IL-25 plays any role in this disease.[9]

IL-25 has potent antitumor activity in vivo in several human cancers including melanoma, breast, lung, colon, and pancreatic cancers, suggesting the potential clinical use of IL-17E as an anticancer agent.[10]

References

  1. ↑ Product reference for IL-17E
  2. ↑ Lee J, Ho WH, Maruoka M, Corpuz RT, Baldwin DT, Foster JS, Goddard AD, Yansura DG, Vandlen RL, Wood WI, Gurney AL (Jan 2001). "IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1". The Journal of Biological Chemistry 276 (2): 1660–4. doi:10.1074/jbc.M008289200. PMID 11058597.
  3. ↑ Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, Menon S, Clifford T, Hunte B, Lesley R, Muchamuel T, Hurst SD, Zurawski G, Leach MW, Gorman DM, Rennick DM (Dec 2001). "IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo". Immunity 15 (6): 985–95. doi:10.1016/S1074-7613(01)00243-6. PMID 11754819.
  4. 1 2 "Entrez Gene: IL25 interleukin 25".
  5. ↑ Ikeda K, Nakajima H, Suzuki K, Kagami S, Hirose K, Suto A, Saito Y, Iwamoto I (May 2003). "Mast cells produce interleukin-25 upon Fc epsilon RI-mediated activation". Blood 101 (9): 3594–6. doi:10.1182/blood-2002-09-2817. PMID 12511410.
  6. ↑ The HGNC site for IL-25
  7. ↑ Owyang AM, Zaph C, Wilson EH, Guild KJ, McClanahan T, Miller HR, Cua DJ, Goldschmidt M, Hunter CA, Kastelein RA, Artis D (Apr 2006). "Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract". The Journal of Experimental Medicine 203 (4): 843–9. doi:10.1084/jem.20051496. PMC: 1800834. PMID 16606667.
  8. ↑ Furuta S, Jeng YM, Zhou L, Huang L, Kuhn I, Bissell MJ, Lee WH (Apr 2011). "IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells". Science Translational Medicine 3 (78): 78ra31. doi:10.1126/scitranslmed.3001374. PMC: 3199022. PMID 21490275. Lay summary – Genetic Engineering & Biotechnology News.
  9. ↑ Büning C, Genschel J, Weltrich R, Lochs H, Schmidt H (Oct 2003). "The interleukin-25 gene located in the inflammatory bowel disease (IBD) 4 region: no association with inflammatory bowel disease". European Journal of Immunogenetics 30 (5): 329–33. doi:10.1046/j.1365-2370.2003.00411.x. PMID 14641539.
  10. ↑ Benatar T, Cao MY, Lee Y, Lightfoot J, Feng N, Gu X, Lee V, Jin H, Wang M, Wright JA, Young AH (Jun 2010). "IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo". Cancer Immunology, Immunotherapy 59 (6): 805–17. doi:10.1007/s00262-009-0802-8. PMID 20012860.

Further reading

  • Fallon PG, Ballantyne SJ, Mangan NE, Barlow JL, Dasvarma A, Hewett DR, McIlgorm A, Jolin HE, McKenzie AN (Apr 2006). "Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion". The Journal of Experimental Medicine 203 (4): 1105–16. doi:10.1084/jem.20051615. PMC: 2118283. PMID 16606668. 
  • Pan G, French D, Mao W, Maruoka M, Risser P, Lee J, Foster J, Aggarwal S, Nicholes K, Guillet S, Schow P, Gurney AL (Dec 2001). "Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice". Journal of Immunology 167 (11): 6559–67. doi:10.4049/jimmunol.167.11.6559. PMID 11714825. 
  • Kim MR, Manoukian R, Yeh R, Silbiger SM, Danilenko DM, Scully S, Sun J, DeRose ML, Stolina M, Chang D, Van GY, Clarkin K, Nguyen HQ, Yu YB, Jing S, Senaldi G, Elliott G, Medlock ES (Oct 2002). "Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production". Blood 100 (7): 2330–40. doi:10.1182/blood-2002-01-0012. PMID 12239140. 
  • Zhang Z, Henzel WJ (Oct 2004). "Signal peptide prediction based on analysis of experimentally verified cleavage sites". Protein Science 13 (10): 2819–24. doi:10.1110/ps.04682504. PMC: 2286551. PMID 15340161. 
  • Létuvé S, Lajoie-Kadoch S, Audusseau S, Rothenberg ME, Fiset PO, Ludwig MS, Hamid Q (Mar 2006). "IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts". The Journal of Allergy and Clinical Immunology 117 (3): 590–6. doi:10.1016/j.jaci.2005.10.025. PMID 16522458. 
  • Tamachi T, Maezawa Y, Ikeda K, Kagami S, Hatano M, Seto Y, Suto A, Suzuki K, Watanabe N, Saito Y, Tokuhisa T, Iwamoto I, Nakajima H (Sep 2006). "IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice". The Journal of Allergy and Clinical Immunology 118 (3): 606–14. doi:10.1016/j.jaci.2006.04.051. PMID 16950278. 
  • Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, Hippe A, Corrigan CJ, Dong C, Homey B, Yao Z, Ying S, Huston DP, Liu YJ (Aug 2007). "IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells". The Journal of Experimental Medicine 204 (8): 1837–47. doi:10.1084/jem.20070406. PMC: 2118667. PMID 17635955. 
This article is issued from Wikipedia - version of the Monday, April 18, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.